Point-Counterpoint: What’s in a Name? Cancer by Any Other Name Is Still Cancer: The Flawed Argument for Renaming Grade Group 1/Gleason Score 3+3=6 Disease

Overview of attention for article published in The Journal of Urology, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter: 12 X users

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 12 X posts from 12 X users, with an upper bound of 60,680 followers.

RT @uroegg: Name change for G6/GG1? Pro (pathologist): https://t.co/XUAjjbZAoe Con (pathologist): https://t.co/RTJWUYQFLQ Pro (clinic…

Pathologist's key argument against name change: "GG1 specifically in the biopsy setting has potentially a diverse & often unpredictable range of clinical outcomes." Replace the word "GG1" with "benign prostate" in this sentence and it remains true.

RT @uroegg: Name change for G6/GG1? Pro (pathologist): https://t.co/XUAjjbZAoe Con (pathologist): https://t.co/RTJWUYQFLQ Pro (clinic…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.